Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders (original) (raw)

Nature volume 494, pages 375–379 (2013) Cite this article

Subjects

Abstract

Insulin resistance is a fundamental pathogenic factor present in various metabolic disorders including obesity and type 2 diabetes1. Although skeletal muscle accounts for 70–90% of insulin-stimulated glucose disposal2,3, the mechanism underlying muscle insulin resistance is poorly understood. Here we show in mice that muscle-specific mitsugumin 53 (MG53; also called TRIM72) mediates the degradation of the insulin receptor and insulin receptor substrate 1 (IRS1), and when upregulated, causes metabolic syndrome featuring insulin resistance, obesity, hypertension and dyslipidaemia. MG53 expression is markedly elevated in models of insulin resistance, and MG53 overexpression suffices to trigger muscle insulin resistance and metabolic syndrome sequentially. Conversely, ablation of MG53 prevents diet-induced metabolic syndrome by preserving the insulin receptor, IRS1 and insulin signalling integrity. Mechanistically, MG53 acts as an E3 ligase targeting the insulin receptor and IRS1 for ubiquitin-dependent degradation, comprising a central mechanism controlling insulin signal strength in skeletal muscle. These findings define MG53 as a novel therapeutic target for treating metabolic disorders and associated cardiovascular complications.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 52 print issues and online access

$199.00 per year

only $3.83 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: MG53 ablation protects mice against diet-induced metabolic syndrome.

The alternative text for this image may have been generated using AI.

Figure 2: MG53 ablation blocks diet-induced systemic insulin resistance.

The alternative text for this image may have been generated using AI.

Figure 3: Overexpression of MG53 triggers systemic insulin resistance and metabolic syndrome.

The alternative text for this image may have been generated using AI.

Figure 4: Regulation of muscle insulin signalling by MG53.

The alternative text for this image may have been generated using AI.

Figure 5: MG53 E3 ligase activates ubiquitination of the insulin receptor and IRS1.

The alternative text for this image may have been generated using AI.

Similar content being viewed by others

References

  1. Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415–1428 (2005)
    Article CAS Google Scholar
  2. DeFronzo, R. A. et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30, 1000–1007 (1981)
    Article CAS Google Scholar
  3. Shulman, G. I. et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322, 223–228 (1990)
    Article CAS Google Scholar
  4. McMillen, I. C. & Robinson, J. S. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol. Rev. 85, 571–633 (2005)
    Article CAS Google Scholar
  5. Grundy, S. M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. 47, 1093–1100 (2006)
    Article CAS Google Scholar
  6. DeFronzo, R. A. & Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 (Suppl. 2). S157–S163 (2009)
    Article CAS Google Scholar
  7. Lillioja, S. et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. 329, 1988–1992 (1993)
    Article CAS Google Scholar
  8. Martin, B. C. et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340, 925–929 (1992)
    Article CAS Google Scholar
  9. Cai, C. et al. MG53 nucleates assembly of cell membrane repair machinery. Nature Cell Biol. 11, 56–64 (2009)
    Article CAS Google Scholar
  10. Cao, C. M. et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121, 2565–2574 (2010)
    Article CAS Google Scholar
  11. Fu, J. et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425, 90–93 (2003)
    Article ADS CAS Google Scholar
  12. Rao, R. H. Insulin resistance in spontaneously hypertensive rats. Difference in interpretation based on insulin infusion rate or on plasma insulin in glucose clamp studies. Diabetes 42, 1364–1371 (1993)
    Article CAS Google Scholar
  13. Zhang, X. et al. Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. Circulation 124, 77–86 (2011)
    Article CAS Google Scholar
  14. Coleman, D. L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141–148 (1978)
    Article CAS Google Scholar
  15. Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001)
    Article ADS CAS Google Scholar
  16. Thirone, A. C., Huang, C. & Klip, A. Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol. Metab. 17, 72–78 (2006)
    Article Google Scholar
  17. Kerouz, N. J., Horsch, D., Pons, S. & Kahn, C. R. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest. 100, 3164–3172 (1997)
    Article CAS Google Scholar
  18. Goodyear, L. J. et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J. Clin. Invest. 95, 2195–2204 (1995)
    Article CAS Google Scholar
  19. Olefsky, J., Bacon, V. C. & Baur, S. Insulin receptors of skeletal muscle: specific insulin binding sites and demonstration of decreased numbers of sites in obese rats. Metabolism 25, 179–191 (1976)
    Article CAS Google Scholar
  20. Capozza, F. et al. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am. J. Physiol. Cell Physiol. 288, C1317–C1331 (2005)
    Article CAS Google Scholar
  21. Zisman, A. et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nature Med. 6, 924–928 (2000)
    Article CAS Google Scholar
  22. Brüning, J. C. et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2, 559–569 (1998)
    Article Google Scholar
  23. Laustsen, P. G. et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell. Biol. 27, 1649–1664 (2007)
    Article CAS Google Scholar
  24. Nakao, R. et al. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. 29, 4798–4811 (2009)
    Article CAS Google Scholar
  25. Ramos, F. J., Langlais, P. R., Hu, D., Dong, L. Q. & Liu, F. Grb10 mediates insulin-stimulated degradation of the insulin receptor: a mechanism of negative regulation. Am. J. Physiol. Endocrinol. Metab. 290, E1262–E1266 (2006)
    Article CAS Google Scholar
  26. Rui, L., Yuan, M., Frantz, D., Shoelson, S. & White, M. F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394–42398 (2002)
    Article CAS Google Scholar
  27. Xu, X. et al. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol. Cell 30, 403–414 (2008)
    Article CAS Google Scholar
  28. Shi, J., Luo, L., Eash, J., Ibebunjo, C. & Glass, D. J. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell 21, 835–847 (2011)
    Article Google Scholar
  29. Joazeiro, C. A. et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286, 309–312 (1999)
    Article CAS Google Scholar
  30. Huang, H. et al. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res. 37, 7560–7569 (2009)
    Article CAS Google Scholar
  31. Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α. Cell 140, 280–293 (2010)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank H. P. Cheng, G. Feng, X. Fu and L. P. Wei for discussions, and S. L. Guo, T. Zhang, X. H. Wang, D. Y. Chen, J. Y. Peng, L. Huang, W. Q. Zhang, N. Hou, L. Pan, L. Chen and Y. L. Liu for their technical support. Special thanks to H. Takeshima and J. J. Ma for their support in providing _MG53_−/− mice. This work was supported by the National Basic Research Program of China (2012CB518000, 2013CB531200, 2012CB944501) and the National Natural Science Foundation of China (81070674, 81070116, 3/22/002 and 81130073).

Author information

Author notes

  1. Ruisheng Song, Wei Peng and Yan Zhang: These authors contributed equally to this work.

Authors and Affiliations

  1. Institute of Molecular Medicine, State Key Laboratory of Biomembrane and Membrane Biotechnology, Peking University, Beijing 100871, China
    Ruisheng Song, Wei Peng, Yan Zhang, Fengxiang Lv, Hong-Kun Wu, Jiaojiao Guo, Li Jin, Mao Zhang, Peng Jiang, Fenghua Liu, Shaoshuai Meng, Xiuqin Zhang, Ping Jiang, Chun-Mei Cao & Rui-Ping Xiao
  2. Institute of Cardiovascular Sciences, Health Science Center, Peking University, Beijing 100083, China
    Ruisheng Song
  3. Institute of Sports Medicine, Peking University Third Hospital, Beijing 100191, China
    Yongxing Cao, Yanbin Pi & Xin Zhang
  4. Center for Life Sciences, Peking University, Beijing 100871, China
    Rui-Ping Xiao

Authors

  1. Ruisheng Song
  2. Wei Peng
  3. Yan Zhang
  4. Fengxiang Lv
  5. Hong-Kun Wu
  6. Jiaojiao Guo
  7. Yongxing Cao
  8. Yanbin Pi
  9. Xin Zhang
  10. Li Jin
  11. Mao Zhang
  12. Peng Jiang
  13. Fenghua Liu
  14. Shaoshuai Meng
  15. Xiuqin Zhang
  16. Ping Jiang
  17. Chun-Mei Cao
  18. Rui-Ping Xiao

Contributions

R.S., W.P. and Y.Z. are equally contributing first authors. R.S. generated the initial idea and conducted key experiments. R.S., W.P., Y.Z., C.-M.C. and R.-P.X. designed the study, analysed the data and wrote the manuscript. C.-M.C. and R.-P.X. interpreted significance of the study. R.S., W.P., Y.Z., F. Lv, H.-K.W., J.G., Y.C., Y.P., Xin Z., L.J., M.Z., Pe.J., F. Liu and S.M. performed the experiments. Pi.J. helped in the generation of MG53 transgenic mice. Xiu.Z. provided the nonhuman primate tissues.

Corresponding authors

Correspondence toChun-Mei Cao or Rui-Ping Xiao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

PowerPoint slides

Rights and permissions

About this article

Cite this article

Song, R., Peng, W., Zhang, Y. et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders.Nature 494, 375–379 (2013). https://doi.org/10.1038/nature11834

Download citation

This article is cited by

Editorial Summary

Muscle enzyme MG53 as drug target

This paper reports the surprising finding that dysregulation of the muscle-specific E3 ligase mitsugumin (MG53) causes insulin resistance and metabolic disorders in mice. When MG53 is upregulated metabolic syndrome ensues; removal of MG53 leaves insulin signalling intact, and prevents diet-induced metabolic syndrome. This work identifies MG53 as a promising therapeutic target for the treatment of metabolic diseases such as type 2 diabetes and associated cardiovascular complications.